Intelligent Antibody Discovery

Therapeutic monoclonal antibodies for medicine

Abeome is a privately-held antibody discovery company focused on the high-throughput selection, analysis and synthesis of monoclonal antibodies with a primary objective to develop best-in-class prescription products for the therapeutic antibody market – the fastest growing segment of global drug sales.

Read More »

Recent News

2017-04-19
Abeome and CDC to Collaborate on Zika Antibody Discovery

Athens, Georgia, April 19, 2017 – Abeome Corporation announced today that it has signed a Research Collaboration Agreement (RCA) with Centers for Disease Control and Prevention (CDC) for the identification of novel antibodies binding to the Zika virus using Abeome’s proprietary AbeoMouseTM platform. “We are very pleased to collaborate with the CDC using our proprietary antibody […]

2017-02-03
Abeome to Present New Data on IL-25 Asthma Program at Keystone Asthma: From Pathway Biology to Precision Therapeutics

Athens, Georgia, February 3, 2017 – Abeome Corporation will present 2 posters at Keystone February 13-16, 2017 describing significant advancements in its IL-25 asthma program. For more information see: Keystone_IL25_Abeome_3026 and: Keystone_IL25_Abeome_1005